Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) is scheduled to be announcing its earnings results before the market opens on Wednesday, August 21st. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.
Chemomab Therapeutics Trading Up 10.9 %
CMMB stock opened at $1.05 on Wednesday. The company’s 50-day moving average price is $1.06 and its 200 day moving average price is $0.86. Chemomab Therapeutics has a 52 week low of $0.42 and a 52 week high of $1.58. The company has a market cap of $11.60 million, a P/E ratio of -0.66 and a beta of 0.50.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on CMMB. Maxim Group raised Chemomab Therapeutics to a “strong-buy” rating in a research note on Friday, May 24th. Oppenheimer upgraded Chemomab Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a research report on Monday, May 6th.
About Chemomab Therapeutics
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
See Also
- Five stocks we like better than Chemomab Therapeutics
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Chipotle Mexican Grill: Take a Bite of This Smoking Hot Deal
- Stock Market Upgrades: What Are They?
- Why O’Reilly Automotive Stock Could Be a Long-Term Winner
- How to Invest in Insurance Companies: A Guide
- Hut 8 Corp.’s Earnings: Is Crypto Mining About to Change?
Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.